Conestoga Capital Micro Cap Composite Q1 2026 Portfolio Holdings

Universal Technical Institute advanced on strong enrollment trends and continued execution of its growth strategy, though near-term profitability is being pressured by reinvestment. Q2 Holdings lagged as investors focused on slower growth and a more moderate outlook. Graham Corp. benefited from improving defense demand, supported by a growing backlog and better program visibility.

Analysis

UTI looks like a classic “reinvestment over margin” setup where the market is likely underappreciating the duration of the compounding engine. In a training/education model, enrollment momentum is the real leading indicator; if that stays intact for another 2-3 quarters, near-term earnings pressure should prove mostly cosmetic and multiple expansion can follow when investors start capitalizing the cohort pipeline rather than current margin. The second-order beneficiary is anyone exposed to labor-shortage end markets, because UTI’s throughput suggests demand is still strong enough that price competition is not yet forcing a sacrifice in quality or fill rates.

QTWO is being punished for something more subtle than a bad quarter: investors are likely discounting the slope of growth, not the absolute level, which matters disproportionately for higher-multiple software. If the deceleration is driven by tougher compares or a deliberate trade-off toward efficiency, the stock can stabilize quickly; if it reflects weaker new-logo momentum, the derating can persist for months because banking/fintech buyers tend to defer rather than cancel. The key read-through is that the market is currently rewarding visible backlog and underweighting reinvestment stories, which creates a gap between price action and fundamental durability.

The contrarian angle is that the “good” and “bad” reactions may both be too extreme. UTI’s spend may be front-loaded, so the market may be extrapolating peak margin pressure into a longer period than is justified, while QTWO may be getting treated as a structural grower even though modest deceleration can compress the premium very fast. The most important catalyst window is the next 1-2 earnings cycles: if UTI shows that enrollment growth converts to incremental margin and QTWO can re-accelerate bookings, the relative performance gap should reverse sharply; if not, the rotation will favor names with clearer visibility and backlog support.

Key Decisions for Investors

• Long UTI on a 1-2 quarter horizon, preferably on pullbacks, with a target that multiple expansion can offset current margin drag if enrollment remains firm; risk is a sudden slowdown in leads/conversion, which would invalidate the thesis quickly.
• Consider a QTWO tactical short or put spread into the next earnings cycle if consensus is still anchored to growth durability; best risk/reward comes from betting that even modest deceleration keeps the multiple compressed over the next 3-6 months.
• Pair trade: long UTI / short QTWO for relative-value exposure to ‘growth with reinvestment’ versus ‘growth with deceleration’; this works best if the market continues to punish slowdown more than it rewards execution.
• If using options, favor QTWO downside structures over outright short equity due to potential squeeze risk on any guide-up; use 1-3 month tenor to capture the next guidance reset.